Cortagen vs Endoluten

Brain cortex-derived tetrapeptide that modulates gene expression in neural and cardiac tissue through chromatin regulatory mechanisms; microarray analysis demonstrates broad transcriptional effects following administration.

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) classified as a Khavinson-class bioregulator derived from cerebral cortex tissue, investigated for gene expression regulatory effects in neural and cardiac tissue. As a Khavinson-class bioregulator, cortagen is proposed to modulate transcriptional activity in aging target tissue by interacting with gene regulatory elements; microarray analysis of cardiac gene expression following cortagen administration has demonstrated broad effects on transcriptional profiles across multiple functional gene categories, suggesting tissue-regulatory activity beyond its cortical tissue origin. Published research on Khavinson-class peptides has further characterized the systematic gene expression regulatory potential of short bioregulator peptides across tissue types, providing the mechanistic context within which cortagen's transcriptional effects are interpreted. Cortagen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical studies with no independent clinical trials published in Western-indexed journals. Cortagen benefits investigated in preclinical research include neuroprotective effects in neural tissue, cardiovascular gene expression modulation, and support for vascular wall integrity in aged animal models. As a brain cortex-derived Khavinson bioregulator, cortagen is proposed to regulate transcription in neural and cardiac tissue through chromatin-level mechanisms, potentially preserving tissue-specific gene expression patterns that decline with aging. Research interest encompasses cortagen's role in neurological aging, post-ischemic brain tissue recovery in preclinical models, and combined bioregulator protocols that pair cortagen with cardiovascular and metabolic peptides for comprehensive longevity applications. Cortagen is a research compound with no regulatory approval in any jurisdiction; evidence is limited to preclinical studies and Russian clinical research literature, with no independent randomized trials published in Western peer-reviewed journals.

Pineal-targeted peptide complex that modulates melatonin synthesis pathways and circadian gene expression. May help restore age-related decline in pineal activity and improve circadian rhythm regulation.

Endoluten is a Khavinson-class peptide bioregulator derived from pineal gland tissue, developed through Vladimir Khavinson's systematic organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, and proposed to restore physiological circadian regulation and melatonin synthesis by modulating gene expression in aging pineal epithelial cells through interaction with chromatin regulatory elements. As a pineal tissue-derived bioregulator, Endoluten operates within the mechanistic framework established for the Khavinson class: short peptides (2–4 amino acids) are proposed to bind specific DNA regulatory sequences in tissue-target cells, activating gene expression programs that decline with age and restoring physiological function through epigenetic mechanisms rather than receptor agonism. Published research on Khavinson-class peptide bioregulators as a class has characterized this peptide-DNA interaction mechanism and documented restorative effects on tissue-specific physiological parameters in aging animal models and human observational studies, providing class-level biological plausibility for pineal peptide bioregulators as age-related circadian and neuroendocrine regulators. Endoluten has no FDA approval and no approved indication in any Western jurisdiction; no indexed published studies using the Endoluten name specifically characterize its clinical outcomes in controlled trials, and its use is confined to the Russian integrative and anti-aging medicine context where Khavinson bioregulators are commercially available.